Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 3, 2004

Primary Completion Date

June 30, 2011

Study Completion Date

December 31, 2013

Conditions
Breast Cancer
Interventions
DRUG

Zoledronic Acid

Zoledronic acid is a new, highly potent, heterocyclic nitrogen-containing third generation bisphosphonate that has demonstrated 40- to 850- fold greater potency than pamidronate in preclinical models of bone resorption. The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway

Trial Locations (1)

94115-1710

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, San Francisco

OTHER